Chemotherapy for advanced colorectal patients: daily practice results may not reflect the outcomes of prospective clinical trials
Abstract
Introduction. Colorectal cancer is the second cause of cancer deaths worldwide. The development of new drugs in recent years has improved the outcomes, but it is not clear whether this progress also includes patients managed in daily clinical practice. Treatment outcomes in patients with advanced colorectal cancer treated in Poland outside of clinical trials are scare.
Methods. We analyzed the results of first-line chemotherapy in 165 patients with advanced colorectal cancer treated between May 2010 and December 2013 in two institutions.
Results. The mean patient age was 61 ± 8.7 years; 105 patients received irinotecan-based regimens (CLF1 or XELIRI), 41 oxaliplatin-based regimens (FOLFOX4 or XELOX) and 19 patients received single-agent 5-fluorouracil. A partial response was achieved in 48 patients (29%), stable disease in 71 (43%) and 46 patients (28%) progressed during treatment. Median survival in the entre group was 14 months. Respective average response rate and median overall survival in recent clinical trials were 39% and 17 months, respectively. Compared to single agent treatment, multidrug chemotherapy was associated with increased general toxicity (p = 0.039), in particular with higher occurrence of diarrhea (p = 0.003) and peripheral neuropathy (p < 0.001). There was no apparent impact of chemotherapy on overall quality of life.
Conclusions. Treatment results of advanced colorectal cancer in daily practice may be worse than those obtained in prospective clinical trials. The use of palliative chemotherapy has no noticeable impact on quality of life.
Keywords: colorectal cancerchemotherapytreatment outcomes
References
- Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr (2013).
- Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce. Centrum Onkologii Instytut, Warszawa 2012.
- De Angelis R, Sant M, Coleman MP, et al. EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014; 15(1): 23–34.
- Biasco G, Derenzini E, Grazi Gl, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev. 2006; 32(3): 214–228.
- Midgley R, Kerr D. Adjuvant chemotherapy for stage II colorectal cancer: who should receive therapy and with what? European Journal of Cancer Supplements. 2005; 3(3): 283–289.
- Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352(9138): 1413–1418.
- Aranda E, Valladares M, Martinez-Villacampa M, et al. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol. 2009; 20(2): 251–257.
- Köhne CH, Wils J, Lorenz M, et al. European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003; 21(20): 3721–3728.
- Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229–237.
- http://groups.eortc.be/qol/eortc-qlq-c30.
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209): 1041–1047.
- Tournigand C, Cervantes A, Figer A, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16): 2938–2947.
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343(13): 905–914.
- Kohne CH, Greve Jde, Bokemeyer C, et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/− celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. Journal of Clinical Oncology. 2005; 23(16_suppl): 3525–3525.
- Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18(1): 136–147.
- Adamowicz K, Jassem J, Katz A, et al. Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treat Rev. 2012; 38(5): 554–558.
- Saad ED, Adamowicz K, Katz A, et al. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev. 2012; 38(6): 807–814.
- Alacacioglu A, Binicier O, Gungor O, et al. Quality of life, anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer. 2010; 18(4): 417–421.